安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- A Randomized Phase 2 Trial of Felzartamab in Antibody . . .
In this phase 2, double-blind, randomized, placebo-controlled trial, we assigned patients with antibody-mediated rejection that had occurred at least 180 days after transplantation to receive
- Felzartamab Shows Potential Therapeutic Benefit, Acceptable . . .
Felzartamab demonstrated a potential therapeutic benefit and an acceptable safety and adverse event (AE) profile in patients with antibody-mediated rejection occurring at least 180 days following a kidney transplant procedure, according to the results of a Phase II trial (NCT05021484) published by The New England Journal of Medicine 1,2
- Felzartamab Effective in Kidney Transplant Rejection
In Part B, all participants will receive felzartamab for an additional open-label period of 6 months through 52 weeks in order to evaluate longer-term activity, safety and tolerability
- New Hope for Kidney Transplant Patients: Promising Results . . .
Participants were randomly assigned to receive either felzartamab or a placebo, with nine infusions administered over 20 weeks This was followed by a 32-week observation period Of the 22 patients enrolled, those receiving felzartamab showed significant improvements compared to the placebo group
- Biogen Initiates Phase 3 Study of Felzartamab for the
In Part B, all participants will receive felzartamab for an additional open-label period of 6 months through 52 weeks in order to evaluate longer-term activity, safety and tolerability
- 225. 3: Randomized phase 2 trial of felzartamab in humoral . . .
Methods: In a double-blind, placebo-controlled phase 2 trial, patients with ABMR ≥180 days post-transplant were randomized 1:1 to receive nine infusions of the CD38 monoclonal antibody felzartamab (16 mg kg) or placebo over 6 months, followed by a 6-month observational period The primary outcome was felzartamab safety and tolerability
- Felzartamab in Late Antibody-Mediated Rejection - Veeva Systems
Participants will be randomized to receive either felzartamab or placebo for a period of six months, and then followed for another six months After six and twelve months, study participants will be subjected to follow-up allograft biopsies
|
|
|